A Threshold Met on Paper: When Does Familial Hypercholesterolemia Earn Apheresis
A 34-year-old man with genetically confirmed heterozygous familial hypercholesterolemia and a non-obstructive coronary lesion numerically meets the criteria for LDL apheresis — whether meeting the threshold on paper means his pharmacologic options are actually exhausted.
Owen T., a 34-year-old software engineer, has known his cholesterol was a problem since he was twelve, when his father died of a heart attack at 41 and a pediatrician, alarmed by a routine screen, referred the whole family for genetic testing. Owen carries a confirmed LDL-receptor mutation, and his untreated LDL before any therapy was measured at 310mg/dL — a number that made the diagnosis of heterozygous familial hypercholesterolemia essentially automatic rather than a judgment call. He has trained himself, in the years since, to treat every new lab result the way he treats a failing unit test: something to be chased down and fixed, not lived with, and it's that instinct that brought him back to clinic within a week of a cardiology referral rather than the six months it usually takes a 34-year-old to act on one.
He has spent the past decade on progressively more aggressive therapy, and today, on high-intensity rosuvastatin, ezetimibe, and alirocumab together, his LDL has come down to 195 — real progress from 310, and still nowhere near goal. His age is the number most likely to be misread here. Thirty-four sounds like room to wait, but arterial risk in familial hypercholesterolemia tracks cumulative LDL exposure rather than current level, and a man who has carried an untreated 310 since childhood and a treated 195 since his twenties has already accumulated more lifetime LDL-years than most people reach in their sixth decade. A stress echocardiogram obtained after an atypical chest tightness during a half-marathon led to a cardiac catheterization that found a 40% mid-LAD lesion, non-flow-limiting on physiologic testing, which is enough to formally establish coronary artery disease but falls well short of the more advanced disease that shaped the original apheresis eligibility criteria. Read against his exposure history, though, that lesion is not an early finding for him; it is the first one anybody happened to look for. On paper, an LDL above 160 with documented CAD despite maximal tolerated therapy meets the threshold for LDL apheresis. Whether his therapy is actually maximal yet is the harder question, since his PCSK9 inhibitor has never been pushed past its standard starting dose — a gap between what the threshold technically requires and what has actually been tried that nobody had flagged until today's visit.
In lipid clinic, a threshold met on paper
On the numbers alone, he qualifies. the FDA-approved apheresis indication, carried forward in the National Lipid Association's own FH guidance, covers heterozygous FH with LDL above 160 despite maximal tolerated therapy in a patient with documented coronary disease, and his LDL sits at 195 on a PCSK9 inhibitor, high-intensity statin, and ezetimibe together. I'd rather refer him for apheresis now, while he's 34 and has decades of exposure ahead of him, than wait for a hard event to force the decision.
The threshold criteria weren't written with a 40% non-obstructive lesion in mind — they were built around patients with more established, often recurrent coronary disease, and Owen's own cardiologist read that lesion as non-flow-limiting. Before committing him to a treatment that means three-to-four-hour sessions every one to two weeks indefinitely, I want to know his alirocumab is actually dosed at its ceiling; he's still on the 75mg every-two-weeks starting dose he was initiated on, and there's a real difference between that and confirming maximal PCSK9 exposure.
Apheresis isn't being ruled out here — it's being asked to wait until the pharmacologic side of this equation is actually maxed out, which it currently isn't.
There's a third option neither of you has raised: evinacumab. It's an ANGPTL3 inhibitor that works independently of the LDL receptor pathway entirely, which matters for a patient whose own receptor is already compromised by his mutation — it's FDA-approved specifically for homozygous FH, not his heterozygous form, so using it here would be off-label, and I want that stated plainly rather than glossed over. But in refractory heFH that isn't responding adequately to maximal receptor-pathway therapy, it's a real, mechanistically distinct option that didn't exist when the apheresis criteria were written.
I'd confirm his PCSK9 dosing is truly maximal first, as the pharmacologist proposed, and only then decide between evinacumab and apheresis if his LDL is still meaningfully above goal — not skip straight to the older, more burdensome option just because it's the one with a formal label for his exact genotype.
Agreed: escalate alirocumab to its maximum labeled dose and recheck LDL in 8 weeks before any apheresis referral goes forward. All three physicians accepted that a threshold met on today's numbers doesn't settle the question if a real dose-escalation step hasn't been tried yet.
Not agreed, and left explicitly open for the follow-up visit: if the escalated dose still leaves him meaningfully above goal, whether the next step is apheresis or a trial of off-label evinacumab. The lipidologist would move to apheresis as the better-established option for his specific genotype; the preventive cardiologist would push for evinacumab first, given its lower burden and a mechanism that doesn't depend on the receptor pathway his own mutation already compromises. Owen was told directly that this second decision has not been made yet and will depend on the recheck.